| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
Nodes: 1975,
Authors: 5409,
Journals: 512,
Outer References: 13295,
Words: 3300
Collection span: 1980 - 2004
View: Overview. Sorted by first author.
Page 5: 1 2 3 4 5 6 7
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 1201 | 0 | 0 | 1623 2003 BLOOD 102(11):382B-382B Musto P; Bodenizza C; Falcone A; Sanpaolo G; Cascavilla N; Melillo L; Dell'Olio M; La Sala A; Mantuano S; Nobile M; Scalzulli PR; Greco MM; Carella AM; Beltrami G; Carella AM Treatment of myeloma patients relapsed after frontline autologous stem cell transplantation with the association of thalidomide, dexamethasone and zoledronate. | 0 | 1 |
| 1202 | 0 | 0 | 1134 2001 BLOOD 98(11):622A-622A Musto P; Falcone A; Bodenizza C; Sanpaolo G; Matera R; Bisceglia M; Carella AM Thalidomide (THAL) significantly improves anemia in selected transfusion-dependent patients with myelodysplastic syndromes (MDS): Relationship to serum and marrow levels of angiogenetic growth factors (AGF). | 0 | 3 |
| 1203 | 3 | 10 | 1464 2002 HAEMATOLOGICA 87(8):884-886 Musto P; Falcone A; Sanpaolo G; Bisceglia M; Matera R; Carella AM Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes | 1 | 1 |
| 1204 | 0 | 0 | 1342 2002 BLOOD 100(11):336B-336B Musto P; Falcone A; Sanpaolo G; Bodenizza C; Bisceglia M; Matera R; Minervini MM; Carella AM Does thalidomide act with different mechanisms of action in myelodysplastic syndromes? | 0 | 0 |
| 1205 | 0 | 0 | 1614 2003 BLOOD 102(11):327B-328B Musto P; Falcone A; Sanpaolo G; Bodenizza C; La Sala A; Carella AM Once-weekly recombinant erythropoietin plus thalidomide for the anemia of low-to-intermediate risk myelodysplastic syndromes. | 0 | 0 |
| 1206 | 0 | 0 | 1359 2002 BLOOD 100(11):388B-388B Musto P; Falcone A; Sanpaolo G; La Sala A; Mantuano S; Cascavilla N; Melillo L; Dell'Olio M; Nobile M; Bodenizza C; Carella AM A combined therapy with thalidomide, dexamethasone and zoledronate is highly effective and well tolerated in pre-treated patients with multiple myeloma. | 0 | 1 |
| 1207 | 0 | 0 | 1868 2004 BRITISH JOURNAL OF CANCER 91:S33-S33 Muthuramalingam SR; Madhusudan S; Vasey PA; Patel P; Christodolus K; Protheroe A; Harris AL A randomised phase II study of interferon-a alone or in combination with thalidomide in metastatic renal cell carcinoma | 0 | 0 |
| 1208 | 1 | 1 | 950 2000 BRITISH JOURNAL OF HAEMATOLOGY 111(3):986-986 Myers B; Crouch D; Dolan G Thalidomide treatment in advanced refractory myeloma | 5 | 5 |
| 1209 | 4 | 4 | 1402 2002 BRITISH JOURNAL OF HAEMATOLOGY 118(1):347-347 Myers B; Dolan G Analysis of durability of response to thalidomide treatment for relapsed myeloma patients | 1 | 1 |
| 1210 | 3 | 4 | 1154 2001 BRITISH JOURNAL OF HAEMATOLOGY 115(1):234-234 Myers B; Grimley C; Crouch D; Dolan G Lack of response to thalidomide in plasmacytomas | 2 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1211 | 1 | 3 | 1153 2001 BRITISH JOURNAL OF HAEMATOLOGY 114(1):245-245 Myers B; Grimley C; Dolan G Thalidomide and low-dose dexamethasone in myeloma treatment | 2 | 3 |
| 1212 | 0 | 0 | 1339 2002 BLOOD 100(11):211A-211A Myers B; Jones SG; McMillan AK; Dolan G Zoledronic acid, hypocalcaemia and renal dysfunction in thalidomide-treated myeloma patients. | 0 | 0 |
| 1213 | 0 | 0 | 1620 2003 BLOOD 102(11):380B-380B Myers B; Russell NH; McMillan AK Use of a novel combination chemotherapy for AL-amyloidosis: Cyclophosphamide, thalidomide and dexamethasone - Serum free light chain (SFLC) and serum amyloid protein P (SAP) scan results. | 0 | 0 |
| 1214 | 10 | 51 | 1163 2001 CANCER LETTERS 163(2):191-200 Myoung H; Hong SD; Kim YY; Hong SP; Kim MJ Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma | 4 | 10 |
| 1215 | 0 | 0 | 1778 2003 LEPROSY REVIEW 74(3):294-295 Naafs B The return of thalidomide: new uses and renewed concerns - reply | 0 | 1 |
| 1216 | 1 | 8 | 43 1982 BRITISH JOURNAL OF DERMATOLOGY 107(1):83-86 NAAFS B; BAKKERS EJM; FLINTERMAN J; FABER WR THALIDOMIDE TREATMENT OF SUB-ACUTE CUTANEOUS LUPUS-ERYTHEMATOSUS | 30 | 44 |
| 1217 | 2 | 3 | 70 1983 BRITISH JOURNAL OF DERMATOLOGY 109(4):479-480 NAAFS B; FABER WR THALIDOMIDE | 0 | 0 |
| 1218 | 11 | 24 | 150 1985 INTERNATIONAL JOURNAL OF DERMATOLOGY 24(2):131-134 NAAFS B; FABER WR THALIDOMIDE THERAPY - AN OPEN TRIAL | 27 | 36 |
| 1219 | 5 | 17 | 1885 2004 CHIRALITY 16:S36-S39 Nakanishi T; Yamakawa N; Asahi T; Shibata N; Ohtani B; Osaka T Chiral discrimination between thalidomide enantiomers using a solid surface with two-dimensional chirality | 0 | 0 |
| 1220 | 1 | 11 | 1797 2003 MEDICAL HYPOTHESES 60(4):513-514 Namazi MR The potential efficacy of thalidomide in the treatment of recalcitrant alopecia areata | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1221 | 2 | 25 | 1542 2002 PEDIATRIC RESEARCH 52(4):576-579 Narita N; Kato M; Tazoe M; Miyazaki K; Narita M; Okado N Increased monoamine concentration in the brain and blood of fetal thalidomide-and valproic acid-exposed rat: Putative animal models for autism | 0 | 3 |
| 1222 | 151 | 187 | 1581 2003 ANNALS OF PHARMACOTHERAPY 37(9):1307-1320 Nasca MR; Micali G; Cheigh NH; West LE; West DP Dermatologic and nondermatologic uses of thalidomide | 1 | 1 |
| 1223 | 25 | 52 | 830 1999 JOURNAL OF INVESTIGATIVE DERMATOLOGY 113(5):720-724 Nasca MR; O'Toole EA; Palicharla P; West DP; Woodley DT Thalidomide increases human keratinocyte migration and proliferation | 6 | 15 |
| 1224 | 0 | 0 | 622 1997 JOURNAL OF INVESTIGATIVE DERMATOLOGY 108(4):179-179 Nasca MR; OToole EA; Palicharla P; West DP; Woodley DT Thalidomide increases both human keratinocyte proliferation and migration | 0 | 0 |
| 1225 | 4 | 4 | 1485 2002 JOURNAL OF CLINICAL ONCOLOGY 20(5):1429-1430 Nathan PD; Gore ME; Eisen TG Unexpected toxicity of combination thalidomide and interferon alfa-2a treatment in metastatic renal cell carcinoma | 8 | 12 |
| 1226 | 5 | 10 | 451 1995 DIGESTIVE DISEASES AND SCIENCES 40(5):1147-1148 NAUM SM; MOLLOY PJ; KANIA RJ; MCGARR J; VANTHIEL DH USE OF THALIDOMIDE IN TREATMENT AND MAINTENANCE OF IDIOPATHIC ESOPHAGEAL ULCERS IN HIV+ INDIVIDUALS | 7 | 11 |
| 1227 | 0 | 6 | 1427 2002 CLINICAL CANCER RESEARCH 8(8):2751-2751 Neben K Correspondence re: K. Neben et al, High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res., 7 : 2675-2681, 2001. Reply | 0 | 0 |
| 1228 | 0 | 0 | 763 1999 BLOOD 94(10):124A-124A Neben K; Hawighorst H; Moehler TM; Egerer G; Punzel M; Van Kaick G; Ho AD; Goldschmidt H Clinical response to thalidomide monotherapy correlates with improvement in dynamic magnetic resonance (d-MRI) angiogenesis parameters. | 0 | 9 |
| 1229 | 17 | 24 | 1428 2002 CLINICAL CANCER RESEARCH 8(11):3377-3382 Neben K; Moehler T; Benner A; Kraemer A; Egerer G; Ho AD; Goldschmidt H Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma | 9 | 13 |
| 1230 | 0 | 0 | 900 2000 BLOOD 96(11):167A-167A Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. | 0 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1231 | 12 | 35 | 1171 2001 CLINICAL CANCER RESEARCH 7(9):2675-2681 Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma | 15 | 29 |
| 1232 | 3 | 12 | 1157 2001 BRITISH JOURNAL OF HAEMATOLOGY 115(3):605-608 Neben K; Moehler T; Kraemer A; Benner A; Egerer G; Ho AD; Goldschmidt H Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion | 20 | 30 |
| 1233 | 0 | 0 | 1107 2001 BLOOD 98(11):163A-163A Neben K; Moehler TM; Benner A; Kraemer A; Ho AD; Goldschmidt H Dose-dependent effect of thalidomide (Thal) on overall survival (OS) in relapsed and refractory multiple myeloma (MM). | 0 | 0 |
| 1234 | 0 | 0 | 1334 2002 BLOOD 100(11):170A-170A Neben K; Mytilineos J; Kraemer A; Moehler TM; Preiss A; Ho AD; Opelz G; Goldschmidt H Thalidomide is able to improve the outcome in patients carrying the high producer haplotype of the interleukin-10 gene promoter in multiple myeloma. | 0 | 0 |
| 1235 | 0 | 0 | 1140 2001 BLOOD 98(11):849A-849A Neben K; Mytilineos J; Moehler TM; Preiss A; Kraemer A; Ho AD; Goldschmidt H Genetic polymorphism in the tumor necrosis factor-alpha locus influences the outcome to thalidomide therapy in relapsed and refractory multiple myeloma (MM). | 0 | 1 |
| 1236 | 3 | 20 | 1324 2002 BLOOD 100(6):2263-2265 Neben K; Mytilineos J; Moehler TM; Preiss A; Kraemer A; Ho AD; Opelz G; Goldschmidt H Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma | 10 | 21 |
| 1237 | 1 | 1 | 191 1986 LEPROSY REVIEW 57(3):273-273 NEELAMKAVIL P SUPPLIES OF THALIDOMIDE FOR USE IN LEPROSY | 1 | 3 |
| 1238 | 4 | 11 | 653 1997 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 17(1):R1-R2 Neubert D Never-ending tales of the mode of the teratogenic action of thalidomide | 3 | 5 |
| 1239 | 0 | 46 | 223 1988 ARCHIVES OF TOXICOLOGY 61(3):180-191 NEUBERT D; HEGER W; MERKER HJ; SAMES K; MEISTER R EMBRYOTOXIC EFFECTS OF THALIDOMIDE DERIVATIVES IN THE NON-HUMAN PRIMATE CALLITHRIX-JACCHUS .2. ELUCIDATION OF THE SUSCEPTIBLE PERIOD AND OF THE VARIABILITY OF EMBRYONIC STAGES | 8 | 21 |
| 1240 | 7 | 45 | 417 1994 LIFE SCIENCES 56(6):407-420 NEUBERT R; HELGE H; NEUBERT D THALIDOMIDE AND THE IMMUNE-SYSTEM .4. DOWN-REGULATION OF THE CD26 RECEPTOR, PROBABLY INVOLVED IN THE BINDING OF HIV COMPONENTS TO T-CELLS IN PRIMATES | 3 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1241 | 14 | 38 | 474 1995 LIFE SCIENCES 58(4):295-316 Neubert R; Hinz N; Thiel R; Neubert D Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide | 3 | 7 |
| 1242 | 4 | 11 | 846 1999 NATURE 400(6743):419-420 Neubert R; Merker HT; Neubert D Developmental model for thalidomide action | 3 | 4 |
| 1243 | 8 | 27 | 333 1992 LIFE SCIENCES 51(26):2107-2116 NEUBERT R; NOGUEIRA AC; NEUBERT D THALIDOMIDE AND THE IMMUNE-SYSTEM .2. CHANGES IN RECEPTORS ON BLOOD-CELLS OF A HEALTHY VOLUNTEER | 32 | 38 |
| 1244 | 31 | 89 | 351 1993 ARCHIVES OF TOXICOLOGY 67(1):1-17 NEUBERT R; NOGUEIRA AC; NEUBERT D THALIDOMIDE DERIVATIVES AND THE IMMUNE-SYSTEM .1. CHANGES IN THE PATTERN OF INTEGRIN RECEPTORS AND OTHER SURFACE-MARKERS ON LYMPHOCYTE-T SUBPOPULATIONS OF MARMOSET BLOOD | 40 | 49 |
| 1245 | 0 | 3 | 185 1986 FOOD AND CHEMICAL TOXICOLOGY 24(6-7):635-636 NEWALL DR; TESH JM EMBRYO CULTURE AS AN EARLY SCREEN FOR TERATOGENIC POTENTIAL .2. THALIDOMIDE | 0 | 2 |
| 1246 | 1 | 38 | 173 1985 TERATOLOGY 32(1):133-144 NEWMAN CGH TERATOGEN UPDATE - CLINICAL ASPECTS OF THALIDOMIDE EMBRYOPATHY - A CONTINUING PREOCCUPATION | 9 | 28 |
| 1247 | 1 | 35 | 182 1986 CLINICS IN PERINATOLOGY 13(3):555-573 NEWMAN CGH THE THALIDOMIDE SYNDROME - RISKS OF EXPOSURE AND SPECTRUM OF MALFORMATIONS | 6 | 19 |
| 1248 | 0 | 0 | 137 1985 AMERICAN JOURNAL OF PRIMATOLOGY 8(4):355-355 NEWMAN L; HENDERICKX A INTERSPECIES VARIATION IN FETAL OTOTEMPOROMANDIBULAR ANOMALIES FOLLOWING MATERNAL THALIDOMIDE EXPOSURE | 0 | 0 |
| 1249 | 0 | 0 | 61 1983 AMERICAN JOURNAL OF PRIMATOLOGY 4(4):336-336 NEWMAN L; HENDRICKX A FETAL DEVELOPMENT IN THE NORMAL AND THALIDOMIDE-EXPOSED THICK-TAILED BUSHBABY | 0 | 0 |
| 1250 | 0 | 40 | 33 1981 TERATOLOGY 23(3):351-364 NEWMAN LM; HENDRICKX AG FETAL EAR MALFORMATIONS INDUCED BY MATERNAL INGESTION OF THALIDOMIDE IN THE BONNET MONKEY (MACACA, RADIATA) | 2 | 13 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1251 | 1 | 20 | 155 1985 JOURNAL OF CRANIOFACIAL GENETICS AND DEVELOPMENTAL BIOLOGY 5(2):147-157 NEWMAN LM; HENDRICKX AG TEMPOROMANDIBULAR MALFORMATIONS IN THE BONNET MONKEY (MACACA-RADIATA) FETUS FOLLOWING MATERNAL INGESTION OF THALIDOMIDE | 0 | 4 |
| 1252 | 0 | 1 | 795 1999 CLINICAL REHABILITATION 13(3):250-252 Newman RJ Shoulder joint replacement for osteoarthrosis in association with thalidomide-induced phocomelia | 0 | 0 |
| 1253 | 30 | 45 | 1312 2002 BIOMEDICINE & PHARMACOTHERAPY 56(4):194-199 Ng SSW; Brown M; Figg WD Thalidomide, an antiangiogenic agent with clinical activity in cancer | 5 | 6 |
| 1254 | 19 | 31 | 1693 2003 CANCER RESEARCH 63(12):3189-3194 Ng SSW; Gutschow M; Weiss M; Hauschildt S; Teubert U; Hecker TK; Luzzio FA; Kruger EA; Eger K; Figg WD Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues | 4 | 6 |
| 1255 | 0 | 0 | 1442 2002 EUROPEAN JOURNAL OF CANCER 38:S82-S82 Ng SSW; Kruger EA; Luzzio FA; Eger K; Guetschow M; Hauschildt S; Hecker T; Teubert U; Weiss M; Figg WD In vitro antiangiogenic activity of thalidomide analogues | 0 | 0 |
| 1256 | 10 | 20 | 1887 2004 CLINICAL CANCER RESEARCH 10(12):4192-4197 Ng SSW; Macpherson GR; Gutschow M; Eger K; Figg WD Antitumor effects of thalidomide analogs in human prostate cancer Xenografts implanted in immunodeficient mice | 0 | 0 |
| 1257 | 9 | 21 | 609 1997 INTERNATIONAL JOURNAL OF ONCOLOGY 10(5):965-969 Nguyen M; Tran C; Barsky S; Sun JR; McBride W; Pegram M; Pietras R; Love S; Glaspy J Thalidomide and chemotherapy combination: Preliminary results of preclinical and clinical studies | 20 | 26 |
| 1258 | 25 | 45 | 1935 2004 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 50(2):235-241 Nguyen YT; Dupuy A; Cordoliani F; Vignon-Pennamen MD; Lebbe C; Morel P; Rybojad M Treatment of cutaneous sarcoidosis with thalidomide | 0 | 0 |
| 1259 | 12 | 27 | 578 1997 BIOCHEMICAL PHARMACOLOGY 53(10):1553-1557 Nicolai S; Sies H; Stahl W Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human skin fibroblasts | 6 | 11 |
| 1260 | 4 | 13 | 274 1990 DICP-THE ANNALS OF PHARMACOTHERAPY 24(11):1054-1056 NICOLAU DP; WEST TE THALIDOMIDE - TREATMENT OF SEVERE RECURRENT APHTHOUS STOMATITIS IN PATIENTS WITH AIDS | 9 | 17 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1261 | 0 | 4 | 121 1984 LANCET 2(8394):98-99 NIELSEN H; BENNIKE T THALIDOMIDE ENHANCES DEFECTIVE MONOCYTE FUNCTION IN LEPROMATOUS LEPROSY | 6 | 8 |
| 1262 | 3 | 14 | 174 1986 ACTA PATHOLOGICA MICROBIOLOGICA ET IMMUNOLOGICA SCANDINAVICA SECTION C-IMMUNOLOGY 94(6):233-237 NIELSEN H; VALERIUS NH THALIDOMIDE ENHANCES SUPEROXIDE ANION RELEASE FROM HUMAN POLYMORPHONUCLEAR AND MONONUCLEAR LEUKOCYTES | 4 | 7 |
| 1263 | 0 | 0 | 1611 2003 BLOOD 102(11):237A-237A Niesvizky R; Pekle K; Lyons L; Pearse RN; Bergsagel PL; Schuster MW; Cho HJ; Leonard JP; Coleman M Dexamethsone alone, or in combination with low-dose thalidomide as induction therapy for advanced multiple myeloma, and the effect of the addition of clarithromycin (Biaxin(TM)) on response rate. interim results of a prospective, sequential, randomized trial. | 0 | 0 |
| 1264 | 0 | 0 | 614 1997 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 278(5):379-379 Nightingale SL Workshop on thalidomide | 0 | 0 |
| 1265 | 0 | 0 | 707 1998 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 280(10):872-872 Nightingale SL Thalidomide approved for erythema nodosum leprosum | 9 | 11 |
| 1266 | 10 | 26 | 1435 2002 DERMATOLOGY 204(4):365-367 Nijsten T; Meuleman L; Schroyens W; Lambert J Thalidomide-induced morbilliform rash: Diagnosis and continuation of therapy, premedicated with methylprednisolone | 0 | 0 |
| 1267 | 0 | 0 | 876 2000 AMERICAN JOURNAL OF HUMAN GENETICS 67(4):134-134 Nippert I 40 years later: The health related quality of life of women affected by Thalidomide. | 0 | 0 |
| 1268 | 6 | 11 | 384 1994 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 199(2):455-460 NISHIMURA K; HASHIMOTO Y; IWASAKI S ENHANCEMENT OF PHORBOL ESTER-INDUCED PRODUCTION OF TUMOR-NECROSIS-FACTOR-ALPHA BY THALIDOMIDE | 27 | 44 |
| 1269 | 7 | 20 | 672 1998 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 8(9):1071-1076 Niwayama S; Loh C; Turk BE; Liu JO; Miyachi H; Hashimoto Y Enhanced potency of perfluorinated thalidomide derivatives for inhibition of LPS-induced tumor necrosis factor-alpha production is associated with a change of mechanism of action | 9 | 11 |
| 1270 | 0 | 0 | 487 1996 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 212:140-MEDI Niwayama S; Turk B; Liu J Potent inhibition of tumor necrosis factor-alpha by tetrafluoro-thalidomide and tetrafluorophthalimides | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1271 | 6 | 31 | 1855 2004 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 14(16):4141-4145 Noguchi T; Sano H; Shimazawa R; Tanatani A; Miyachi H; Hashimoto Y Phenylhomophthalimide-type NOS inhibitors derived from thalidomide | 0 | 0 |
| 1272 | 8 | 30 | 1315 2002 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 12(7):1043-1046 Noguchi T; Shimazawa R; Nagasawa K; Hashimoto Y Thalidomide and its analogues as cyclooxygenase inhibitors | 12 | 15 |
| 1273 | 11 | 24 | 475 1995 LIFE SCIENCES 58(4):337-348 Nogueira AC; Neubert R; Felies A; JacobMuller U; Frankus E; Neubert D Thalidomide derivatives and the immune system .6. Effects of two derivatives with no obvious teratogenic potency on the pattern of integrins and other surface receptors on blood cells of marmosets | 2 | 3 |
| 1274 | 8 | 27 | 416 1994 LIFE SCIENCES 55(2):77-92 NOGUEIRA AC; NEUBERT R; HELGE H; NEUBERT D THALIDOMIDE AND THE IMMUNE-SYSTEM .3. SIMULTANEOUS UP-REGULATION AND DOWN-REGULATION OF DIFFERENT INTEGRIN RECEPTORS ON HUMAN WHITE BLOOD-CELLS | 56 | 63 |
| 1275 | 0 | 0 | 963 2000 CLINICAL PHARMACOLOGY & THERAPEUTICS 67(2):157-157 Noormohamed FH; Yoder L; Kook KA; Thomas SD Thalidomide pharmacokinetics in leprosy patients. | 0 | 0 |
| 1276 | 22 | 30 | 745 1999 AIDS RESEARCH AND HUMAN RETROVIRUSES 15(12):1047-1052 Noormohamed FH; Youle MS; Higgs CJ; Kook KA; Hawkins DA; Lant AF; Thomas SD Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects | 13 | 13 |
| 1277 | 0 | 0 | 65 1983 AUSTRALIAN PAEDIATRIC JOURNAL 19(3):198-198 NORTH K; MCCREDIE J THALIDOMIDE DEFORMITIES AND THEIR NERVE SUPPLY | 0 | 0 |
| 1278 | 0 | 4 | 62 1983 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 110(6-7):551-552 NOUGUE J; NOUGUE M; BAZEX J; HAYEK JP; BIDOUZE H OCCURRENCE OF A GENITAL HEMORRHAGIC DURING A THALIDOMIDE TREATED PRURIGO NODULARIS | 3 | 3 |
| 1279 | 0 | 0 | 1624 2003 BLOOD 102(11):382B-382B Novoselac AV; Reddy S; Ohsumi F; Sherman RE; Samaha S Acute myeloid leukemia in patient with multiple myeloma treated with thalidomide. | 0 | 0 |
| 1280 | 0 | 0 | 1374 2002 BLOOD 100(11):402A-402A Oakervee HE; McBride NC; Hemmaway CJ; Brownell A; Cervi P; Crawley C; Gale R; Grant I; Hamblin M; Lewis D; Rahemtulla A; Barnett MJ; Cavenagh JD Thalidomide combined with vincristine, adriamycin and dexamethasone (T-VAD) is effective treatment for multiple myeloma and does not prejudice successful stem cell harvesting. | 0 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1281 | 11 | 33 | 404 1994 EUROPEAN JOURNAL OF DERMATOLOGY 4(1):9-15 OCHONISKY S; REVUZ J THALIDOMIDE USE IN DERMATOLOGY | 29 | 34 |
| 1282 | 12 | 23 | 382 1994 ARCHIVES OF DERMATOLOGY 130(1):66-69 OCHONISKY S; VERROUST J; BASTUJIGARIN S; GHERARDI R; REVUZ J THALIDOMIDE NEUROPATHY INCIDENCE AND CLINICOELECTROPHYSIOLOGIC FINDINGS IN 42 PATIENTS | 73 | 97 |
| 1283 | 1 | 8 | 1465 2002 HAUTARZT 53(2):150-150 Ochsendorf F; Kaufman R Thalidomide in the treatment of cutaneous and systemic sarcoidosis | 0 | 0 |
| 1284 | 0 | 0 | 59 1982 TERATOLOGY 26(3):A19-A19 OCKENFELS H; KOCHERBECKER U; KOCHER W EFFECTS OF SINGLE AND COMBINED ACTION OF A HYDROLYSIS PRODUCT OF THALIDOMIDE AND THE SURFACTANT TWEEN 20 IN MICE | 0 | 0 |
| 1285 | 1 | 3 | 626 1997 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 25(2):250-251 Odeka EB; Miller V Thalidomide in oral Crohn's disease refractory to conventional medical treatment | 17 | 0 |
| 1286 | 15 | 30 | 1897 2004 EUROPEAN JOURNAL OF HAEMATOLOGY 72(6):403-409 Offidani M; Corvatta L; Marconi M; Malerba L; Mele A; Olivieri A; Brunori M; Catarini M; Candela M; Capelli D; Montanari M; Rupoli S; Leoni P Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy | 0 | 0 |
| 1287 | 0 | 0 | 1622 2003 BLOOD 102(11):381B-381B Offidani M; Marconi M; Corvatta L; Malerba L; Olivieri A; Barulli S; Capelli D; Rupoli S; Leoni P Combination therapy with Caelyx, dexamethasone and thalidomide (CDT) for multiple myeloma (MM): Preliminary results of a phase II-III study. | 0 | 0 |
| 1288 | 0 | 0 | 1864 2004 BONE MARROW TRANSPLANTATION 33:S165-S165 Offidani M; Marconi M; Corvatta L; Malerba L; Olivieri A; Mele A; Galieni P; Centurioni R; Alesiani F; Candela M; Leoni P Combination thalidomide, doxil and dexamethasone as salvage therapy for patients relapsed after tandem autotransplant | 0 | 0 |
| 1289 | 4 | 10 | 1727 2003 HAEMATOLOGICA 88(12):1432-1433 Offidani M; Marconi M; Corvotta L; Olivieri A; Catarini M; Leoni P Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study | 0 | 1 |
| 1290 | 0 | 0 | 1125 2001 BLOOD 98(11):311B-311B Offidani M; Mele A; Marconi M; Corvatta L; Candela M; Pieroni S; Malerba L; Rupoli S; Olivieri A; Leoni P Thalidomide plus melphalan in relapsed-refractory multiple myeloma. | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1291 | 41 | 78 | 1812 2003 PHARMACOTHERAPY 23(4):481-493 Okafor MC Thalidomide for erythema nodosum leprosum and other applications | 0 | 0 |
| 1292 | 0 | 0 | 1618 2003 BLOOD 102(11):366B-367B Okikawa Y; Sakai A; Kuroda Y; Katayama Y; Takimoto Y; Okita H; Kimura A Analysis of the maturity of myeloma cells (plasma cells) is useful to select effective chemotherapy including thalidomide and to predict the progressive disease. | 0 | 0 |
| 1293 | 9 | 19 | 1916 2004 INTERNATIONAL JOURNAL OF HEMATOLOGY 79(4):364-368 Okikawa Y; Sakai A; Takimoto Y; Noda M; Imagawa J; Katayama Y; Kuroda Y; Okita H; Fujimura K; Kimura A Progressive myeloma after thalidomide therapy in a patient with immature phenotype of myeloma (plasma) cells | 0 | 0 |
| 1294 | 0 | 0 | 436 1995 ARTHRITIS AND RHEUMATISM 38(6):R10-R10 OLIVER SJ; CHENG TP; BANQUERIGO ML; BRAHN E THALIDOMIDE ANALOGS SUPPRESS RAT COLLAGEN ARTHRITIS | 1 | 2 |
| 1295 | 10 | 33 | 716 1998 JOURNAL OF RHEUMATOLOGY 25(5):964-969 Oliver SJ; Cheng TP; Banquerigo ML; Brahn E The effect of thalidomide and 2 analogs on collagen induced arthritis | 16 | 32 |
| 1296 | 9 | 31 | 790 1999 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 118(2):315-321 Oliver SJ; Freeman SL; Corral LG; Ocampo CJ; Kaplan G Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis | 9 | 13 |
| 1297 | 0 | 0 | 666 1998 ARTHRITIS AND RHEUMATISM 41(9):S98-S98 Oliver SJ; Freeman SL; Kaplan G Thalidomide and analog CC1089 in rat adjuvant arthritis. | 0 | 0 |
| 1298 | 12 | 49 | 1429 2002 CLINICAL IMMUNOLOGY 102(3):225-236 Oliver SJ; Kikuchi T; Krueger JG; Kaplan G Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement | 4 | 8 |
| 1299 | 0 | 0 | 756 1999 ARTHRITIS AND RHEUMATISM 42(9):S187-S187 Oliver SJ; Moreira A; Kaplan G Reduced fibrosis and normalization of skin structure in scleroderma patients treated with thalidomide. | 1 | 5 |
| 1300 | 13 | 49 | 960 2000 CLINICAL IMMUNOLOGY 97(2):109-120 Oliver SJ; Moreira A; Kaplan G Immune stimulation in scleroderma patients treated with thalidomide | 11 | 15 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1301 | 0 | 0 | 757 1999 ARTHRITIS AND RHEUMATISM 42(9):S276-S276 Oliver SJ; Moreira A; Ozawa M; Krueger JG; Kaplan G Beneficial effects of thalidomide in sarcoidosis are associated with an enhanced Th1-type immune response | 0 | 0 |
| 1302 | 5 | 12 | 811 1999 GUT 45(3):463-464 Ollivier S; Bonnet J; Lemann M; Coffin JC; Modigliani R; Jian R; Bertheau P; Flejou JF Idiopathic giant oesophageal ulcer in an immunocompetent patient. The efficacy of thalidomide treatment | 1 | 2 |
| 1303 | 2 | 23 | 1085 2001 BIOCHEMICAL PHARMACOLOGY 62(8):1081-1086 Onat D; Stahl W; Sies H Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human fetal skin fibroblasts (HFFF2) and in rat liver epithelial cells (WB-F344) | 2 | 3 |
| 1304 | 7 | 25 | 1172 2001 CLINICAL CANCER RESEARCH 7(11):3311-3313 Onn A; Tseng JE; Herbst RS Thalidomide, cyclooxygenase-2, and angiogenesis: Potential for therapy | 2 | 11 |
| 1305 | 0 | 0 | 552 1996 NEUROLOGY 46(2):3015-3015 Openshaw H; Slatkin NE; Parker P Thalidomide neuropathy in bone marrow transplantation | 0 | 0 |
| 1306 | 29 | 60 | 697 1998 EXPERIMENTAL HEMATOLOGY 26(3):217-221 Or R; Feferman R; Shoshan S Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs | 18 | 24 |
| 1307 | 0 | 0 | 760 1999 ARTHRITIS AND RHEUMATISM 42(10):2260-2260 Ordi J; Cortes F; Balada E; Mauri M; Vilardell M Ovarian failure with thalidomide treatment in complex aphthosis: comment on the concise communication by Ordi et al - Reply | 0 | 0 |
| 1308 | 6 | 13 | 668 1998 ARTHRITIS AND RHEUMATISM 41(12):2273-2275 Ordi J; Cortes F; Martinez N; Mauri M; De Torres I; Vilardell M Thalidomide induces amenorrhea in patients with lupus disease | 13 | 20 |
| 1309 | 17 | 27 | 1015 2000 JOURNAL OF RHEUMATOLOGY 27(6):1429-1433 Ordi-Ros J; Cortes F; Cucurull E; Mauri M; Bujan S; Vilardell M Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy | 15 | 28 |
| 1310 | 0 | 0 | 667 1998 ARTHRITIS AND RHEUMATISM 41(9):S108-S108 Ordi-Ros J; Cortes F; Martinez N; Montse M; De Torres I; Vilardell M Thalidomide induces amenorrhea in patients with lupus disease. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1311 | 3 | 4 | 1249 2001 NEW ENGLAND JOURNAL OF MEDICINE 344(25):1951-1952 Osman K; Comenzo R; Rajkumar SV Deep venous thrombosis and thalidomide therapy for multiple myeloma. | 46 | 59 |
| 1312 | 75 | 130 | 1423 2002 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 20(5):709-718 Ossandon A; Cassara EAM; Priori R; Valesini G Thalidomide: focus on its employment in rheumatologic diseases | 2 | 4 |
| 1313 | 3 | 7 | 341 1992 TRANSPLANTATION PROCEEDINGS 24(6):2624-2625 OSTRAAT O; EKBERG H; SCHATZ H; RIESBECK K; ERIKSSON T THALIDOMIDE PROLONGS GRAFT-SURVIVAL IN RAT CARDIAC TRANSPLANTS | 9 | 9 |
| 1314 | 0 | 0 | 594 1997 CLINICAL PHARMACOLOGY & THERAPEUTICS 61(2):PI44-PI44 OToole EA; Nasca MR; Palicharla P; West DP; Woodley DT Thalidomide increases keratinocyte proliferation and chemokine secretion in vitro | 0 | 0 |
| 1315 | 0 | 0 | 1019 2000 LEPROSY REVIEW 71:S120-S120 Ottenhoff THM; Kaplan G; Gillis TP Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions - Discussion | 0 | 0 |
| 1316 | 0 | 0 | 1633 2003 BLOOD 102(11):390B-390B Oyan B; Koc Y; Kars A; Turker A; Tekuzman G; Kansu E Achieving high remission rate with use of autologous HSCT, thalidomide maintenance and non-myeloablative allogeneic HSCT in patients with multiple myeloma. | 0 | 0 |
| 1317 | 0 | 0 | 536 1996 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 37(3):546-546 Ozaki S; Yamana T; Kita M; Honda Y Effect of thalidomide on experimental choroidal neovascularization in pigmented rats | 0 | 0 |
| 1318 | 5 | 7 | 1953 2004 LUPUS 13(6):481-482 Pagnoux C; Lutz-Zarrouk V; Michel M; Schaeffer A; Godeau B Cerebral venous thrombosis in a patient with antiphospholipid syndrome treated with thalidomide | 0 | 0 |
| 1319 | 0 | 0 | 1370 2002 BLOOD 100(11):397A-397A Palladini G; Perfetti V; Obici L; Merlini G Thalidomide toxicity in patients with AL (primary) amyloidosis. | 0 | 4 |
| 1320 | 0 | 0 | 1338 2002 BLOOD 100(11):211A-211A Palumbo A; Bertola A; Cavallo F; Falco P; Bringhen S; Giaccone L; Musto P; Pregno P; Boccadoro M Low-dose thalidomide and dexamethasone improves survival in advanced multiple myeloma. | 0 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1321 | 0 | 0 | 1607 2003 BLOOD 102(11):148A-148A Palumbo A; Bertola A; Musto P; Nunzi M; De Stefano V; Callea V; Rotoli B; Petti MC; Caravita T; Lauta VM; Patti C; Bringhen S; Cavallo F; Falco P; Carella AM; Liberati AM; Boccadoro M Oral melphalan, prednisone and thalidomide for newly diagnosed myeloma. | 0 | 1 |
| 1322 | 0 | 0 | 918 2000 BLOOD 96(11):292B-292B Palumbo A; Giaccone L; Bertola A; Bringhen S; Rus C; Triolo S; Pileri A; Boccadoro M Thalidomide and dexamethasone as salvage therapy for refractory and relapsed myeloma. | 0 | 6 |
| 1323 | 7 | 27 | 1200 2001 HAEMATOLOGICA 86(4):399-403 Palumbo A; Giaccone L; Bertola A; Pregno P; Bringhen S; Rus C; Triolo S; Gallo E; Pileri A; Boccadoro M Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma | 25 | 38 |
| 1324 | 0 | 0 | 1100 2001 BLOOD 98(11):162A-162A Palumbo A; Giaccone L; Bringhen S; Cavallo F; Falco P; Rus C; Bertola A; Pileri A; Boccadoro M Low dose thalidomide and dexamethasone are as effective as oral melphalan and prednisone in refractory and relapsed myeloma patients. | 0 | 4 |
| 1325 | 0 | 0 | 1569 2003 AMERICAN JOURNAL OF HUMAN GENETICS 73(5):286-286 Pan P; Omlin K; Rosenthal J; Padilla O; Stadecker M; Demmer L A case of Restrictive Dermopathy with survival beyond the neonatal period and novel experience with thalidomide therapy | 0 | 0 |
| 1326 | 2 | 20 | 1775 2003 LEPROSY REVIEW 74(3):286-288 Pannikar V The return of thalidomide: new uses and renewed concerns | 0 | 1 |
| 1327 | 6 | 15 | 1258 2001 OPHTHALMOLOGICA 215(1):70-73 Parentin F; Da Pozzo S; Lepore L; Perissutti P Thalidomide effectiveness for bilateral chronic idiopathic anterior uveitis in a three-year-old child | 2 | 2 |
| 1328 | 0 | 0 | 1598 2003 ATHEROSCLEROSIS SUPPLEMENTS 4(2):28-28 Park SJ Thalidomide as a potent inhibitor of neointimal hyperplasia after balloon injury in rat carotid artery | 0 | 0 |
| 1329 | 11 | 36 | 1848 2004 ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 24(5):885-891 Park SJ; Kim HS; Yang HM; Park KW; Youn SW; Jeon SI; Kim DH; Koo BK; Chae IH; Choi DJ; Oh BH; Lee MM; Park YB Thalidomide as a potent inhibitor of neointimal hyperplasia after balloon injury in rat carotid artery | 0 | 0 |
| 1330 | 6 | 25 | 439 1995 BLOOD 86(9):3604-3609 PARKER PM; CHAO N; NADEMANEE A; ODONNELL MR; SCHMIDT GM; SNYDER DS; STEIN AS; SMITH EP; MOLINA A; STEPAN DE; KASHYAP A; PLANAS I; SPIELBERGER R; SOMLO G; MARGOLIN K; ZWINGENBERGER K; WILSMAN K; NEGRIN RS; LONG GD; NILAND JC; BLUME KG; FORMAN SJ THALIDOMIDE AS SALVAGE THERAPY FOR CHRONIC GRAFT-VERSUS-HOST DISEASE | 51 | 85 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1331 | 0 | 0 | 386 1994 BLOOD 84(10):A335-A335 PARKER PM; NADEMANEE A; ODONNELL MR; SNYDER DS; STEIN A; SMITH E; MOLINA A; STEPAN DE; CHAO N; NILAND JC; BLUME KG; FORMAN SJ NEUTROPENIA IS A COMPLICATION OF THALIDOMIDE THERAPY FOR CHRONIC GRAFT-VERSUS-HOST DISEASE | 0 | 0 |
| 1332 | 0 | 29 | 100 1983 TERATOLOGY 27(3):327-332 PARKHIE M; WEBB M EMBRYOTOXICITY AND TERATOGENICITY OF THALIDOMIDE IN RATS | 3 | 7 |
| 1333 | 10 | 25 | 849 1999 NATURE MEDICINE 5(5):582-585 Parman T; Wiley MJ; Wells PG Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity | 65 | 111 |
| 1334 | 2 | 25 | 704 1998 INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY 116(1):60-66 Partida-Sanchez S; Favila-Castillo L; Pedraza-Sanchez S; Gomez-Melgar M; Saul A; Estrada-Parra S; Estrada-Garcia I IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment | 9 | 13 |
| 1335 | 4 | 4 | 1150 2001 BRITISH JOURNAL OF DERMATOLOGY 144(6):1292-1293 Passeron T; Lacour JP; Murr D; Ortonne JP Thalidomide-induced amenorrhoea: two cases | 4 | 4 |
| 1336 | 23 | 38 | 450 1995 CLINICAL INFECTIOUS DISEASES 20(2):250-254 PATERSON DL; GEORGHIOU PR; ALLWORTH AM; KEMP RJ THALIDOMIDE AS TREATMENT OF REFRACTORY APHTHOUS ULCERATION RELATED TO HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION | 38 | 60 |
| 1337 | 1 | 6 | 258 1989 GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE 13(1):104-104 PATEY O; CHARASZ N; ROUCAYROL AM; MALKIN JE; LAFAIX C THALIDOMIDE AND INTESTINAL INVOLVEMENT IN BEHCETS SYNDROME | 2 | 3 |
| 1338 | 2 | 3 | 1711 2003 DIABETES CARE 26(4):1322-1323 Pathak RD; Jayaraj K; Blonde L Thalidomide-associated hyperglycemia and diabetes - Case report and review of literature | 0 | 0 |
| 1339 | 0 | 0 | 1392 2002 BONE MARROW TRANSPLANTATION 29:S104-S104 Patriarca F; Fill C; Sperotto A; Damiani D; Zaja F; Cerno M; Fanin R Thalidomide overcomes VAD chemoresistance and allows PBSC collection in 3 multiple myeloma patients | 0 | 0 |
| 1340 | 3 | 10 | 1725 2003 HAEMATOLOGICA 88(5):597-599 Patriarca F; Sperotto A; Prosdocimo S; Geromin A; Zaja F; Fanin R Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1341 | 0 | 0 | 1663 2003 BONE MARROW TRANSPLANTATION 31:S78-S79 Patriarca F; Sperotto A; Prosdocimo S; Geromin A; Zaja F; Fili C; Cerno M; Fanin R Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients | 0 | 0 |
| 1342 | 3 | 14 | 874 2000 AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS 23(3):319-321 Patt YZ; Hassan MM; Lozano RD; Ellis LM; Peterson JA; Waugh KA Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide | 14 | 26 |
| 1343 | 0 | 0 | 1636 2003 BLOOD 102(11):449A-449A Patten PE; Ahsan G; Kazmi M; Fields PA; Chick GW; Jones RR; Bradwell AR; Schey SA The early use of the serum free light chain assay in patients with relapsed refractory myeloma receiving treatment with a thalidomide analogue (CC-4047). | 0 | 0 |
| 1344 | 10 | 32 | 1962 2004 MELANOMA RESEARCH 14(1):57-62 Pawlak WZ; Legha SS Phase II study of thalidomide in patients with metastatic melanoma | 0 | 0 |
| 1345 | 0 | 2 | 1409 2002 BRITISH JOURNAL OF PHARMACOLOGY 137 Paxton JW; Kestell P; Ding Q; Ching LM; Zhou S; Palmer BD; Baguley BC Preliminary investigations into the pharmacokinetic interaction between cyclophosphamide and thalidomide in the mouse | 0 | 0 |
| 1346 | 0 | 0 | 935 2000 BLOOD 96(11):579A-+ Payvandi F; Wu L; Gupta D; Hideshima T; Haley M; Muller G; Chen R; Anderson KC; Stirling S Effects of a thalidomide analog on binding activity of transcription factors and cell cycle progression of multiple myeloma cell lines. | 0 | 1 |
| 1347 | 0 | 0 | 1348 2002 BLOOD 100(11):371B-371B Payvandi F; Wu L; Zhang LH; Muller G; Chen R; Stengel J; Harriri R; Stirling D Thalidomide and IMiDs inhibit microvessel formation from human arterial rings in the absence of human liver microsomes. | 0 | 0 |
| 1348 | 1 | 3 | 374 1993 PRESSE MEDICALE 22(1):37-37 PEDAILLES S; TROUSSARD X; LAUNAY V; BAZIN A; SENTIAS C; SURBLED M SCLERODERMATOUS SKIN REACTION IN GRAFT-VERSUS-HOST DISEASE TREATED WITH THALIDOMIDE | 2 | 2 |
| 1349 | 43 | 65 | 1563 2003 AMERICAN JOURNAL OF CLINICAL DERMATOLOGY 4(6):379-387 Pelle MT; Werth VP Thalidomide in cutaneous lupus erythematosus | 0 | 0 |
| 1350 | 5 | 32 | 1776 2003 LEPROSY REVIEW 74(3):288-290 Pereira GFM On thalidomide and VMO policies | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1351 | 3 | 5 | 889 2000 ARCHIVES OF OPHTHALMOLOGY 118(1):135-136 Periman LM; Sires BS Full-thickness skin grafting of eyelids in a patient with generalized morphea taking thalidomide | 1 | 1 |
| 1352 | 12 | 35 | 1854 2004 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 14(2):421-425 Perino S; Contino-Pepin C; Satchi-Fainaro R; Butterfield C; Pucci B Inhibition of angiogenesis by THAM-derived cotelomers endowed with thalidomide moieties | 0 | 0 |
| 1353 | 3 | 15 | 1207 2001 HAUTARZT 52:966-969 Petering H; Kiehl P; Vogelbruch M; Sticht-Groh V; Kapp A; Werfel T Chemotherapy-induced erythema nodosum leprosum: successful treatment with thalidomide | 0 | 0 |
| 1354 | 4 | 22 | 434 1995 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 39(12):2807-2809 PETERSON PK; GEKKER G; BORNEMANN M; CHATTERJEE D; CHAO CC THALIDOMIDE INHIBITS LIPOARABINOMANNAN-INDUCED UP-REGULATION OF HUMAN-IMMUNODEFICIENCY-VIRUS EXPRESSION | 3 | 10 |
| 1355 | 3 | 15 | 466 1995 JOURNAL OF INFECTIOUS DISEASES 172(4):1137-1140 PETERSON PK; HU SX; SHENG WS; KRAVITZ FH; MOLITOR TW; CHATTERJEE D; CHAO CC THALIDOMIDE INHIBITS TUMOR-NECROSIS-FACTOR-ALPHA PRODUCTION BY LIPOPOLYSACCHARIDE-STIMULATED AND LIPOARABINOMANNAN-STIMULATED HUMAN MICROGLIAL CELLS | 20 | 33 |
| 1356 | 0 | 0 | 931 2000 BLOOD 96(11):366A-366A Petrucci MT; Ricciardi MR; Gregorj C; Palumbo G; Del Bianco P; Cartoni C; Mandelli F; Tafuri A Thalidomide effects on apoptosis in multiple myeloma: Ex-vivo and in vitro study. | 0 | 1 |
| 1357 | 41 | 120 | 971 2000 DRUGS 60(2):273-292 Peuckmann V; Fisch M; Bruera E Potential novel uses of thalidomide - Focus on palliative care | 27 | 40 |
| 1358 | 35 | 95 | 1817 2003 SCHMERZ 17(3):204-+ Peuckmann V; Strumpf M; Zenz M; Bruera E Novel potential uses of thalidomide in the management of pain? A review of the literature | 0 | 0 |
| 1359 | 15 | 27 | 608 1997 INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY 19(5):289-296 Pham-Huy C; Galons H; Voisin J; Zhu JR; Righenzi S; Warnet JM; Claude JR; Duc HT In vitro and in vivo immunosuppressive potential of thalidomide and its derivative, N-hydroxythalidomide, alone and in combination with cyclosporin A | 1 | 1 |
| 1360 | 1 | 4 | 1538 2002 ONCOLOGY-NEW YORK 16(3):276-+ Phuphanich S Recurrent multicentric glioblastoma multiforme responds to thalidomide and chemotherapy | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1361 | 0 | 0 | 938 2000 BLOOD 96(11):746A-746A Piccaluga PP; Finelli C; Ricci P; Cavo M; Pileri SA; Isidori A; Malagola M; Grafone T; Tura S; Visani G Antiangiogenic therapy with thalidomide improves anemia, thrombocytopenia, hyperleucocytosis, splenomegaly in idiopathic myelofibrosis. | 0 | 4 |
| 1362 | 11 | 38 | 1518 2002 LEUKEMIA 16(9):1609-1614 Piccaluga PP; Visani G; Pileri SA; Ascani S; Grafone T; Isidori A; Malagola M; Finelli C; Martinelli G; Ricci P; Baccarani M; Tura S Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study | 8 | 13 |
| 1363 | 17 | 38 | 1526 2002 LUPUS 11(2):67-70 Piette JC; Sbai A; Frances C Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus | 3 | 5 |
| 1364 | 5 | 11 | 1849 2004 ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH 51(3):505-506 Pillemer SR; Leakan RA; Sankar V; Manny J; Baum BJ; Smith J; Chaudhry U; Fox PC; Radfar L; Ligier S; Brennan MT Prominent adverse effects of thalidomide in primary Sjogren's syndrome | 0 | 0 |
| 1365 | 4 | 9 | 985 2000 HAEMATOLOGICA 85(10):1111-1112 Pini M; Baraldi A; Pietrasanta D; Allione B; Depaoli L; Salvi F; Levis A Low-dose thalidomide in the treatment of refractory myeloma | 11 | 19 |
| 1366 | 0 | 0 | 18 1981 INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES 49(4):511-512 PIPER LM; AGRAWAL KC; HASTINGS RC ANTI-INFLAMMATORY IMMUNOSUPPRESSIVE THALIDOMIDE ANALOGS - SCREENING | 0 | 0 |
| 1367 | 5 | 26 | 1931 2004 JOURNAL OF NEURO-ONCOLOGY 66(3):295-299 Piribauer M; Czech T; Dieckmann K; Birner P; Hainfellner JA; Prayer D; Fazeny-Dorner B; Weinlander G; Marosi C Stabilization of a progressive hemangioblastoma under treatment with thalidomide | 0 | 0 |
| 1368 | 12 | 21 | 576 1997 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 41(12):2797-2799 Piscitelli SC; Figg WD; Hahn B; Kelly G; Thomas S; Walker RE Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients | 22 | 25 |
| 1369 | 2 | 6 | 1664 2003 BONE MARROW TRANSPLANTATION 31(11):1065-1065 Pitini V; Arrigo C; Aloi G; Micali C; La Gattuta G Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT | 0 | 0 |
| 1370 | 3 | 5 | 1404 2002 BRITISH JOURNAL OF HAEMATOLOGY 119(1):275-275 Pitini V; Teti D; Arrigo C; Aloi G Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1371 | 6 | 10 | 816 1999 INTERNATIONAL JOURNAL OF DERMATOLOGY 38(1):76-77 Pizarro A; Garcia-Tobaruela A; Herranz P; Pinilla J Thalidomide as an inhibitor of tumor necrosis factor-alpha production: a word of caution | 1 | 1 |
| 1372 | 3 | 10 | 369 1993 MEDICINA CLINICA 101(4):158-158 PIZARRO A; PINILLA J; GARCIATOBARUELA A THERAPY WITH THALIDOMIDE AND TUMOR-NECROSIS-FACTOR-ALPHA PRODUCTION | 0 | 1 |
| 1373 | 4 | 10 | 1024 2000 MEDICINA-BUENOS AIRES 60:61-65 Politi PM Thalidomide. Clinical trials in cancer. | 1 | 1 |
| 1374 | 2 | 17 | 515 1996 CANCER LETTERS 101(1):21-24 Pollard M Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA-III) in L-W rats | 8 | 12 |
| 1375 | 0 | 0 | 735 1998 NEUROLOGY 50(4):A208-A208 Poncelet AN; Maurer TA; Wu ZQ; Ng J; Badger J; Berger TG Peripheral neuropathy in HIV-infected patients with prurigo nodularis treated with thalidomide: Clinical and electrophysiologic features | 0 | 0 |
| 1376 | 53 | 61 | 1541 2002 ORAL ONCOLOGY 38(6):527-531 Porter SR; Jorge J Thalidomide: a role in oral oncology? | 0 | 1 |
| 1377 | 2 | 14 | 525 1996 EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY 8(9):929-931 Postema PTE; denHaan P; vanHagen PM; vanBlankenstein M Treatment of colitis in Behcet's disease with thalidomide | 12 | 20 |
| 1378 | 13 | 19 | 1972 2004 THROMBOSIS AND HAEMOSTASIS 91(4):834-836 Potenza L; Luppi M; Morselli M; Saviola A; Ferrari A; Riva G; Longo G; Marietta M; Torelli G Thrombotic complications associated with thalidomide in multiple myeloma: an old problem with new questions and quandaries in decision-making | 0 | 0 |
| 1379 | 4 | 6 | 1399 2002 BRITISH JOURNAL OF DERMATOLOGY 146(6):1112-1113 Pouaha J; Martin S; Reichert-Penetrat S; Trechot P; Barbaud A; Schmutz JL Thalidomide and sexual dysfunction in men | 0 | 0 |
| 1380 | 2 | 3 | 1262 2001 PRESSE MEDICALE 30(20):1008-1009 Pouaha J; Martin S; Trechot P; Truchetet F; Barbaud A; Schmutz JL Thalidomide and thrombosis: three cases | 5 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1381 | 6 | 11 | 514 1996 BRITISH MEDICAL JOURNAL 313(7054):377-378 Powell RJ New roles for thalidomide | 18 | 24 |
| 1382 | 48 | 79 | 761 1999 BIODRUGS 11(6):409-416 Powell RJ Thalidomide - Current uses | 1 | 2 |
| 1383 | 6 | 13 | 144 1985 BRITISH JOURNAL OF DERMATOLOGY 113:141-144 POWELL RJ; ALLEN BR; JENKINS JS; STEELE L; HUNNEYBALL I; MAURICE PDL; LITTLEWOOD SM INVESTIGATION AND TREATMENT OF OROGENITAL ULCERATION - STUDIES ON A POSSIBLE MODE OF ACTION OF THALIDOMIDE | 7 | 9 |
| 1384 | 4 | 13 | 423 1994 POSTGRADUATE MEDICAL JOURNAL 70(830):901-904 POWELL RJ; GARDNERMEDWIN JMM GUIDELINE FOR THE CLINICAL USE AND DISPENSING OF THALIDOMIDE | 39 | 53 |
| 1385 | 6 | 16 | 632 1997 LEPROSY REVIEW 68(1):61-66 Powell RJ; GardnerMedwin JMM Guideline for the clinical use and dispensing of thalidomide (Reprinted from the Postgraduate Medical Journal, vol 70, pg 901-904, 1994) | 1 | 3 |
| 1386 | 2 | 9 | 1204 2001 HAEMATOLOGICA 86(7):772-773 Pozzato G; Zorat F; Nascimben F; Comar C; Kikic F; Festini G Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia | 7 | 11 |
| 1387 | 10 | 27 | 1221 2001 JOURNAL OF CLINICAL IMMUNOLOGY 21(5):357-364 Prehn JL; Landers C; Muller GW; Man HW; Stirling DI; Targan SR Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues | 3 | 4 |
| 1388 | 0 | 0 | 981 2000 GASTROENTEROLOGY 118(4):A586-A586 Prehn JL; Muller GW; Man HW; Stirling DJ; Targan SR Thalidomide analogs, but not thalidomide itself, are potent inhibitors of lamina propria mononuclear cell (LPMC) TNF-A and IFN-Gamma production in response to T cell stimuli. | 0 | 0 |
| 1389 | 22 | 34 | 1554 2002 THERAPEUTIC DRUG MONITORING 24(1):104-110 Price DK; Ando Y; Kruger EA; Weiss M; Figg WD 5 '-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis | 9 | 10 |
| 1390 | 2 | 4 | 95 1983 PRESSE MEDICALE 12(47):3007-3007 PRIGENT F; OUAZZANI W SARCOIDOSIS OF THE SKIN - TREATMENT WITH THALIDOMIDE | 4 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1391 | 0 | 0 | 919 2000 BLOOD 96(11):293B-293B Prince HM; Biagi JJ; Mitchell P; Mileshkin L; Seymour JF; Januszewicz EH; Wolf MM; Westerman DA Interferon-alpha-2b (IF) can be combined with thalidomide (Thal) in patients with multiple myeloma (MM). | 0 | 3 |
| 1392 | 0 | 0 | 1373 2002 BLOOD 100(11):401A-402A Prince M; Mileshkin L; Biagi JJ; Smith JG; Mitchell P; Underhill C; Grigg A; Bell R; McKendrick J; Briggs P; Seymour JF; Simmons PJ; Zeldis JB A multicentre phase-II trial of thalidomide in relapsed/refractory multiple myeloma (MM) reveals a dominant adverse prognostic impact of advanced age. | 0 | 0 |
| 1393 | 7 | 8 | 1878 2004 CANCER 100(6):1186-1189 Pro B; Younes A; Albitar M; Dang NH; Samaniego F; Romaguera J; McLaughlin P; Hagemeister FB; Rodriguez MA; Clemons M; Cabanillas F Thalidomide for patients with recurrent lymphoma | 0 | 0 |
| 1394 | 0 | 0 | 1114 2001 BLOOD 98(11):246B-246B Pro B; Younes A; Albitar M; Hagemeister FB; Rodriguez MA; McLaughlin P; Clemons M; Samaniego F; Cabanillas F Phase II study of thalidomide in patients with recurrent Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHL). | 0 | 0 |
| 1395 | 3 | 3 | 1288 2002 AMERICAN JOURNAL OF HEMATOLOGY 70(3):265-265 Pulik M; Genet P; Lionnet F; Touahri T Thalidomide-associated gynecomasty in a patient with multiple myeloma | 1 | 1 |
| 1396 | 0 | 3 | 25 1981 PRACTITIONER 225(1355):721-& QUIBELL EP THE THALIDOMIDE EMBRYOPATHY - AN ANALYSIS FROM THE UK | 9 | 13 |
| 1397 | 2 | 13 | 283 1990 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 23(3):523-525 RADEFF B; KUFFER R; SAMSON J RECURRENT APHTHOUS ULCER IN PATIENT INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS - SUCCESSFUL TREATMENT WITH THALIDOMIDE | 18 | 30 |
| 1398 | 92 | 115 | 1177 2001 DERMATOLOGIC CLINICS 19(1):87-+ Radomsky CL; Levine N Thalidomide | 4 | 8 |
| 1399 | 8 | 17 | 853 1999 NEW ENGLAND JOURNAL OF MEDICINE 341(21):1606-1609 Raje N; Anderson K Thalidomide - A revival story. | 48 | 87 |
| 1400 | 33 | 53 | 1434 2002 CURRENT OPINION IN ONCOLOGY 14(6):635-640 Raje N; Anderson KC Thalidomide and immunomodulatory drugs as cancer therapy | 8 | 14 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1401 | 0 | 0 | 1037 2000 ONCOLOGY-NEW YORK 14(12):9-10 Rajkumar SV Thalidomide in hematologic and oncologic disease - Proceedings of an Investigators' Meeting - May 20, 2000, New Orleans - Introduction | 2 | 2 |
| 1402 | 12 | 57 | 1038 2000 ONCOLOGY-NEW YORK 14(12):11-16 Rajkumar SV Thalidomide in multiple myeloma | 9 | 17 |
| 1403 | 28 | 70 | 1254 2001 ONCOLOGY-NEW YORK 15(7):867-874 Rajkumar SV Current status of thalidomide in the treatment of cancer | 9 | 14 |
| 1404 | 10 | 33 | 1821 2003 SEMINARS IN HEMATOLOGY 40(4):17-22 Rajkumar SV Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease | 0 | 0 |
| 1405 | 50 | 83 | 1957 2004 MAYO CLINIC PROCEEDINGS 79(7):899-903 Rajkumar SV Thalidomide: Tragic past and promising future | 0 | 0 |
| 1406 | 10 | 19 | 1239 2001 LEUKEMIA 15(8):1274-1276 Rajkumar SV; Dispenzieri A; Fonseca R; Lacy MQ; Geyer S; Lust JA; Kyle RA; Greipp PR; Gertz MA; Witzig TE Thalidomide for previously untreated indolent or smoldering multiple myeloma | 28 | 43 |
| 1407 | 0 | 0 | 1103 2001 BLOOD 98(11):162A-163A Rajkumar SV; Dispenzieri A; Lacy M; Geyer S; Iturria N; Fonseca R; Hayman SR; Lust JA; Kyle R; Greipp PR; Gertz MA; Witzig TE Response rate and durablity of response with thalidomide therapy for relapsed multiple myeloma (MM). | 0 | 4 |
| 1408 | 10 | 28 | 1023 2000 MAYO CLINIC PROCEEDINGS 75(9):897-901 Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Kyle RA; Gertz MA; Greipp PR Thalidomide in the treatment of relapsed multiple myeloma | 56 | 85 |
| 1409 | 0 | 0 | 776 1999 BLOOD 94(10):316A-316A Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Witzig TE; Lust JA; Kyle RA; Gertz MA; Greipp PR Thalidomide in the treatment of relapsed and refractory myeloma. | 0 | 9 |
| 1410 | 3 | 5 | 1078 2001 ARCHIVES OF INTERNAL MEDICINE 161(20):2502-2503 Rajkumar SV; Fonseca R; Witzig TE Complete resolution of reflex sympathetic dystrophy with thalidomide treatment | 3 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1411 | 1 | 1 | 1591 2003 ARCHIVES OF INTERNAL MEDICINE 163(12):1488-1488 Rajkumar SV; Fonseca R; Witzig TE Thalidomide has activity in treating complex regional pain syndrome - Reply | 0 | 0 |
| 1412 | 2 | 2 | 1528 2002 MAYO CLINIC PROCEEDINGS 77(12):1395-1395 Rajkumar SV; Gertz MA; Kyle RA; Greipp PR Thalidomide-induced neuropathy - In reply | 0 | 0 |
| 1413 | 0 | 0 | 1377 2002 BLOOD 100(11):403A-404A Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A; Fonseca R; Geyer S; Iturria N; Kumar S; Lust JA; Kyle RA; Greipp PR; Witzig TE Single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. | 0 | 0 |
| 1414 | 12 | 32 | 1780 2003 LEUKEMIA 17(4):775-779 Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A; Fonseca R; Geyer SM; Iturria N; Kumar S; Lust JA; Kyle RA; Greipp PR; Witzig TE Thalidomide as initial therapy for early-stage myeloma | 12 | 19 |
| 1415 | 4 | 6 | 1033 2000 NEW ENGLAND JOURNAL OF MEDICINE 343(13):972-973 Rajkumar SV; Gertz MA; Witzig TE Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. | 23 | 33 |
| 1416 | 0 | 0 | 904 2000 BLOOD 96(11):168A-168A Rajkumar SV; Hayman S; Fonseca R; Dispenzieri A; Lacy MQ; Geyer S; Wellik L; Lust JA; Kyle RA; Greipp PR; Gertz MA; Witzig TE Thalidomide plus dexamethasone (Thal/Dex) and thalidomide alone (Thal) as first line therapy for newly diagnosed myeloma (MM). | 0 | 24 |
| 1417 | 21 | 37 | 1490 2002 JOURNAL OF CLINICAL ONCOLOGY 20(21):4319-4323 Rajkumar SV; Hayman S; Gertz MA; Dispenzieri A; Lacy MQ; Greipp PR; Geyer S; Iturria N; Fonseca R; Lust JA; Kyle RA; Witzig TE Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma | 33 | 57 |
| 1418 | 0 | 0 | 1139 2001 BLOOD 98(11):849A-849A Rajkumar SV; Hayman SR; Gertz MA; Dispenzieri A; Lacy M; Greipp PR; Geyer S; Itturia N; Fonseca R; Lust JA; Kyle R; Witzig TE Combination therapy with thalidomide plus dexamethasone (THAL/DEX) for newly diagnosed myeloma (MM). | 0 | 5 |
| 1419 | 18 | 26 | 1222 2001 JOURNAL OF CLINICAL ONCOLOGY 19(16):3593-3595 Rajkumar SV; Kyle RA Thalidomide in the treatment of plasma cell malignancies | 6 | 7 |
| 1420 | 0 | 0 | 930 2000 BLOOD 96(11):364A-364A Rajkumar SV; Timm M; Mesa RA; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Gertz MA; Kyle RA; Griepp PR; Witzig TE Effect of thalidomide on myeloma cell apoptosis and VEGF secretion. | 0 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1421 | 20 | 98 | 954 2000 CANCER TREATMENT REVIEWS 26(5):351-362 Rajkumar SV; Witzig TE A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma | 29 | 53 |
| 1422 | 2 | 6 | 1786 2003 LEUKEMIA 17(11):2238-2238 Rajkumar SV; Witzig TE Thalidomide as anti-inflammatory therapy for multiple myeloma - Reply | 0 | 0 |
| 1423 | 4 | 10 | 792 1999 CLINICAL INFECTIOUS DISEASES 28(4):892-894 Ramirez-Amador VA; Esquivel-Pedraza L; Ponce-de-Leon S; Reyes-Teran G; Gonzalez-Guevara M; Ponce-de-Leon S; Sierra-Madero JG Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: A double-blind placebo-controlled clinical trial | 4 | 5 |
| 1424 | 7 | 27 | 179 1986 BRITISH JOURNAL OF DERMATOLOGY 115(3):367-370 RAMSELAAR CG; BOONE RM; KLUINNELEMANS HC THALIDOMIDE IN THE TREATMENT OF NEURO-BEHCETS SYNDROME | 10 | 20 |
| 1425 | 0 | 6 | 278 1990 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 263(11):1467-1468 RANDALL T THALIDOMIDE BACK IN THE NEWS, BUT IN MORE FAVORABLE CIRCUMSTANCES | 7 | 21 |
| 1426 | 0 | 2 | 279 1990 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 263(11):1473-1473 RANDALL T RESEARCH FOCUSES ON IMMUNOSUPPRESSIVE EFFECT, UNKNOWN TERATOGENIC MECHANISM OF THALIDOMIDE | 2 | 2 |
| 1427 | 0 | 1 | 280 1990 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 263(11):1474-1474 RANDALL T INVESTIGATIONAL NEW DRUG (US) ORPHAN TRIALS NOW USE THALIDOMIDE FROM 2 SOURCES | 8 | 12 |
| 1428 | 4 | 5 | 1027 2000 MUSCLE & NERVE 23(8):1301-1302 Rao DG; Kane NM; Oware A Thalidomide neuropathy: Role of F-wave monitoring | 5 | 5 |
| 1429 | 8 | 12 | 1066 2001 AMERICAN JOURNAL OF GASTROENTEROLOGY 96(11):3207-3209 Raufman JP; Lamps LW Thalidomide-induced normalization of serum ALT levels in a patient with hepatitis C | 0 | 0 |
| 1430 | 12 | 70 | 800 1999 DRUGS 58(6):953-963 Ravot E; Lisziewicz J; Lori F New uses for old drugs in HIV infection - The role of hydroxyurea, cyclosporin and thalidomide | 3 | 15 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1431 | 1 | 41 | 1952 2004 LEUKEMIA RESEARCH 28(8):791-803 Raza A; Buonamici S; Lisak L; Tahir S; Li DL; Imran M; Chaudary NI; Pervaiz H; Gallegos JA; Alvi MI; Mumtaz M; Gezer S; Venugopal P; Reddy P; Galili N; Candoni A; Singer J; Nucifora G Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression | 0 | 0 |
| 1432 | 0 | 0 | 1117 2001 BLOOD 98(11):273B-274B Raza A; Dutt D; Lisak L; Dean L; Fantroy L; Gezer S; Syed E; Goldberg C; Loew J; Hsu WT; Venugopal P Combination of thalidomide and Enbrel for the treatment of patients with myelodysplastic syndromes (MDS). | 0 | 0 |
| 1433 | 0 | 0 | 783 1999 BLOOD 94(10):661A-661A Raza A; Lisak L; Andrews C; Little L; Muzammil M; Alvi S; Mazzoran L; Zorat F; Akber A; Ekbal M; Razvi S; Venugopal P Thalidomide produces transfusion independence in patients with long-standing refractory anemias and myelodysplastic syndromes (MDS). | 0 | 9 |
| 1434 | 0 | 0 | 1116 2001 BLOOD 98(11):273B-273B Raza A; Lisak L; Dutt D; Dean L; Fantroy L; Syed E; Gezer S; Hsu WT; Goldberg C; Loew J; Venugopal P Combination of thalidomide with pentoxifylline, ciprofloxacin, and dexamethasone (PCD) in patients with myelodysplastic syndromes (MDS). | 0 | 0 |
| 1435 | 0 | 0 | 976 2000 EXPERIMENTAL HEMATOLOGY 28(7):103-104 Raza A; Lisak L; Little L; Andrews C; Meyer P; Ekbal M; Venugopal P Improvement in cytopenias of patients with myelodysplastic syndromes (MDS) in response to thalidomide | 0 | 0 |
| 1436 | 0 | 0 | 897 2000 BLOOD 96(11):146A-146A Raza A; Lisak L; Little L; Ekbal M; du Rant M; Ali E; Nascimben F; Tareen M; Venugopal P Thalidomide as a single agent or in combination with topotecan, pentoxifylline and/or Enbrel in myelodysplastic syndromes (MDS). | 0 | 6 |
| 1437 | 0 | 0 | 1344 2002 BLOOD 100(11):340B-340B Raza A; Lisak LA; Tahir S; Billmeier JM; Willmann HS; Alvi MI; Bellak DJ; Gezer S; Venugopal P Combination of thalidomide and etanercept (Tumor necrosis factor receptor OR TNFR) effective in improving the cytopenias of some patients with myelodysplastic syndromes (MDS). | 0 | 2 |
| 1438 | 0 | 0 | 1382 2002 BLOOD 100(11):795A-795A Raza A; Lisak LA; Tahir S; Billmeier JM; Willmann HS; Alvi MI; Patkar S; Khan T; Rizvi A; Venugopal P; Gezer S; Mundle SD; Reddy PL Trilineage responses to arsenic trioxide (Trisenox (R)) and thalidomide in patients with myelodysplastic syndromes (MDS), particularly those with inv(3)(q21q26.2). | 0 | 0 |
| 1439 | 12 | 59 | 1095 2001 BLOOD 98(4):958-965 Raza A; Meyer P; Dutt D; Zorat F; Lisak L; Nascimben F; du Randt M; Kaspar C; Goldberg C; Loew J; Dar S; Gezer S; Venugopal P; Zeldis J Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes | 29 | 64 |
| 1440 | 0 | 0 | 906 2000 BLOOD 96(11):168A-169A Raza SN; Veksler Y; Sabir T; Li ZJ; Anderson L; Jagannath S Durable response to thalidomide in relapsed/refractory multiple myeloma (MM). | 0 | 7 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1441 | 0 | 3 | 393 1994 BRITISH MEDICAL JOURNAL 308(6944):1636-1636 READ AP THALIDOMIDE MAY BE A MUTAGEN - COMMENT | 12 | 14 |
| 1442 | 10 | 28 | 516 1996 CHIRALITY 8(1):11-17 Reepmeyer JC Separation of R-and S-thalidomide by reversed-phase HPLC with beta-cyclodextrin in the mobile phase | 6 | 18 |
| 1443 | 18 | 23 | 620 1997 JOURNAL OF AOAC INTERNATIONAL 80(4):767-773 Reepmeyer JC; Cox DC Liquid chromatographic determination of thalidomide in tablets, capsules, and raw materials | 0 | 4 |
| 1444 | 9 | 20 | 411 1994 JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 2 (9):2063-2067 REEPMEYER JC; RHODES MO; COX DC; SILVERTON JV CHARACTERIZATION AND CRYSTAL-STRUCTURE OF 2 POLYMORPHIC FORMS OF RACEMIC THALIDOMIDE | 3 | 4 |
| 1445 | 11 | 41 | 686 1998 CHEMICAL RESEARCH IN TOXICOLOGY 11(12):1521-1528 Reist M; Carrupt PA; Francotte E; Testa B Chiral inversion and hydrolysis of thalidomide: Mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites | 15 | 17 |
| 1446 | 41 | 106 | 267 1990 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 117(4):313-321 REVUZ J THALIDOMIDE | 16 | 21 |
| 1447 | 0 | 0 | 175 1986 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 113(5):499-499 REVUZ J; COTTENOT F; ORTONNE JP; GUILLAUME JC THALIDOMIDE ON TRIAL | 0 | 0 |
| 1448 | 15 | 26 | 268 1990 ARCHIVES OF DERMATOLOGY 126(7):923-927 REVUZ J; GUILLAUME JC; JANIER M; HANS P; MARCHAND C; SOUTEYRAND P; BONNETBLANC JM; CLAUDY A; DALLAC S; KLENE C; CRICKX B; SANCHOGARNIER H; CHAUMEIL JC CROSSOVER STUDY OF THALIDOMIDE VS PLACEBO IN SEVERE RECURRENT APHTHOUS STOMATITIS | 53 | 100 |
| 1449 | 5 | 38 | 490 1996 AIDS 10(13):1501-1507 ReyesTeran G; SierraMadero JG; delCerro VM; ArroyoFigueroa H; Pasquetti A; Calva JJ; RuizPalacios GM Effects of thalidomide on HIV-associated wasting syndrome: A randomized, double-blind, placebo-controlled clinical trial | 49 | 98 |
| 1450 | 8 | 15 | 362 1993 GASTROENTEROLOGY 105(3):956-956 RHOTON AJ ROLE FOR THALIDOMIDE IN PRIMARY BILIARY-CIRRHOSIS TREATMENT | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1451 | 3 | 6 | 1832 2004 ACTA ONCOLOGICA 43(2):215-216 Ribas C; Colleoni G; Almeida M; Duch CR; Ohashi C; Segreto R; Silva MR Response of plasmacytomas to low-dose thalidomide in a patient with refractory multiple myeloma | 0 | 0 |
| 1452 | 13 | 57 | 1787 2003 LEUKEMIA & LYMPHOMA 44(2):291-298 Ribas C; Colleoni GWB Advances in the treatment of multiple myeloma: The role of thalidomide | 0 | 1 |
| 1453 | 2 | 5 | 1575 2003 ANNALS OF HEMATOLOGY 82(4):262-262 Ribatti A; Vacca A On the use of thalidomide as an antiangiogenic agent in the treatment of multiple myeloma | 0 | 0 |
| 1454 | 13 | 20 | 1461 2002 HAEMATOLOGICA 87(4):344-345 Ribatti D; Vacca A Is thalidomide a true anti-angiogenic molecule in multiple myeloma? | 1 | 1 |
| 1455 | 10 | 34 | 975 2000 EUROPEAN JOURNAL OF PHARMACOLOGY 391(1-2):97-103 Ribeiro RA; Vale ML; Ferreira SH; Cunha FQ Analgesic effect of thalidomide on inflammatory pain | 3 | 18 |
| 1456 | 18 | 28 | 1537 2002 ONCOLOGY-NEW YORK 16(1):22-24 Richardson P; Anderson K Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease - Drs. Paul Richardson and Kenneth Anderson respond | 0 | 0 |
| 1457 | 9 | 16 | 1923 2004 JOURNAL OF CLINICAL ONCOLOGY 22(16):3212-3214 Richardson P; Anderson K Immunomodulatory analogs of thalidomide: An emerging new therapy in myeloma | 0 | 0 |
| 1458 | 63 | 112 | 1298 2002 ANNUAL REVIEW OF MEDICINE 53:629-657 Richardson P; Hideshima T; Anderson K Thalidomide: Emerging role in cancer medicine | 23 | 36 |
| 1459 | 50 | 93 | 1311 2002 BIOMEDICINE & PHARMACOTHERAPY 56(3):115-128 Richardson P; Hideshima T; Anderson K Thalidomide in multiple myeloma | 5 | 6 |
| 1460 | 0 | 0 | 1386 2002 BLOOD 100(11):813A-813A Richardson P; Jagannath S; Schlossman R; Alsina M; Desikan RK; Blood E; Weller E; Mitsiades C; Hideshima T; Davies F; Doss D; Freeman A; Bosch J; Patin J; Dalton W; Anderson KC Thalidomide for relapsed multiple myeloma after high dose therapy and stem cell transplantation: Results of an open-label, multicenter phase two study of efficacy, toxicity and correlation with biological activity. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1461 | 12 | 22 | 1955 2004 MAYO CLINIC PROCEEDINGS 79(7):875-882 Richardson P; Schlossman R; Jagannath S; Alsina M; Desikan R; Blood E; Weller E; Mitsiades C; Hideshima T; Davies F; Doss D; Freeman A; Bosch J; Patin J; Knight R; Zeldis J; Dalton W; Anderson K Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: Results of an open-label Multicenter phase 2 study of efficacy, toxicity, and biological activity | 1 | 1 |
| 1462 | 0 | 0 | 1137 2001 BLOOD 98(11):775A-775A Richardson PG; Schlossman RL; Hideshima T; Davies F; LeBlanc R; Catley L; Doss D; Kelly KA; McKenney M; Mechlowicz J; Freeman A; Deocampo R; Rich R; Ryoo J; Chauhan D; Munshi N; Weller E; Thomas S; Zeldis J; Anderson KC A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM). | 0 | 10 |
| 1463 | 0 | 0 | 77 1983 CHELSEA (42-4):237-237 RIDLAND J THE 'THALIDOMIDE KIDS ON TELEVISION (1978)' | 0 | 0 |
| 1464 | 11 | 23 | 752 1999 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 43(9):2305-2306 Ridoux O; Drancourt M Lack of in vitro antimicrosporidian activity of thalidomide | 1 | 1 |
| 1465 | 0 | 0 | 401 1994 CLINICAL RESEARCH 42(2):A142-A142 RIFKIN IR; MCHUGH SM; BRADLEY JR; THIRU S; EWAN PW; LOCKWOOD CM INDUCTION OF TH2, AND INHIBITION OF TH1, LYMPHOCYTE-RESPONSES BY THALIDOMIDE | 0 | 0 |
| 1466 | 0 | 0 | 472 1995 KIDNEY INTERNATIONAL 47(2):672-672 RIFLKIN IR; MCHUGH SM; BRADLEY JR; THIRU S; EWAN PW; LOCKWOOD CM THALIDOMIDE AS TREATMENT FOR REFRACTORY SYSTEMIC VASCULITIS - POSSIBLE MECHANISM OF ACTION | 0 | 0 |
| 1467 | 2 | 3 | 237 1988 LANCET 2(8610):568-568 RINGDEN O; ASCHAN J; WESTERBERG L THALIDOMIDE FOR SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE | 8 | 9 |
| 1468 | 0 | 0 | 558 1996 REPRODUCTIVE TOXICOLOGY 10(1):1-2 Robert E Thalidomide and isotretinoin - Why treat them differently? | 2 | 6 |
| 1469 | 10 | 16 | 1749 2003 JOURNAL OF INFECTION 47(3):251-255 Roberts MTM; Mendelson M; Meyer P; Carmichael A; Lever AML The use of thalidomide in the treatment of intracranial tuberculomas in adults: two case reports | 0 | 0 |
| 1470 | 3 | 18 | 486 1995 TETRAHEDRON-ASYMMETRY 6(6):1249-1252 ROBIN S; ZHU J; GALONS H; PHAMHUY C; CLAUDE JR; TOMAS A; VIOSSAT B A CONVENIENT ASYMMETRIC-SYNTHESIS OF THALIDOMIDE | 8 | 19 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1471 | 0 | 0 | 390 1994 BRITISH MEDICAL JOURNAL 308(6936):1061-1061 ROCHA J THALIDOMIDE GIVEN TO WOMEN IN BRAZIL | 3 | 4 |
| 1472 | 11 | 22 | 1808 2003 PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS 33:15-18 Rodeghiero F; Elice F Thalidomide and thrombosis | 1 | 2 |
| 1473 | 0 | 0 | 920 2000 BLOOD 96(11):294B-294B Rodriguez J; Oyama Y; Burt RK; Traynor AE Achievement of maximal disease response to thalidomide is limited by patient tolerance more often than disease resistance. | 0 | 4 |
| 1474 | 0 | 2 | 115 1984 GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE 8(2):196-196 ROGE J; TESTAS P THALIDOMIDE IN BEHCETS SYNDROME | 6 | 7 |
| 1475 | 10 | 29 | 1891 2004 CYTOKINE 26(4):145-148 Rosinol L; Cibeira MT; Segarra M; Cid MC; Filella X; Aymerich M; Rozman M; Arenillas L; Esteve J; Blade J; Montserrat E Response to thalidomide in multiple myeloma: impact of angiogenic factors | 0 | 0 |
| 1476 | 9 | 32 | 1910 2004 HAEMATOLOGICA 89(7):832-836 Rosinol L; Cibeira T; Blade J; Esteve J; Aymerich M; Rozman M; Segarra M; Cid MC; Filella X; Montserrat E Extramedullary multiple myeloma escapes the effect of thalidomide | 0 | 0 |
| 1477 | 2 | 34 | 377 1993 SPECTROSCOPY LETTERS 26(4):597-619 ROTHCHILD R; SANDERS K; VENKATASUBBAN KS NMR-STUDIES OF DRUGS - USE OF LANTHANIDE SHIFT-REAGENTS IN POLAR-SOLVENT WITH THALIDOMIDE | 0 | 6 |
| 1478 | 4 | 5 | 664 1998 ARCHIVES OF DERMATOLOGY 134(8):1045-1046 Rousseau L; Beylot-Barry M; Doutre MS; Beylot C Cutaneous sarcoidosis successfully treated with low doses of thalidomide | 12 | 25 |
| 1479 | 14 | 23 | 681 1998 BONE MARROW TRANSPLANTATION 21(6):577-581 Rovelli A; Arrigo C; Nesi F; Balduzzi A; Nicolini B; Locasiulli A; Vassallo E; Miniero R; Uderzo C The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children | 27 | 37 |
| 1480 | 19 | 33 | 703 1998 IMMUNOPHARMACOLOGY 40(1):11-20 Rowland TL; McHugh SM; Deighton J; Dearman RJ; Ewan PW; Kimber I Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells | 36 | 48 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1481 | 15 | 32 | 812 1999 IMMUNOLOGY LETTERS 68(2-3):325-332 Rowland TL; McHugh SM; Deighton J; Ewan PW; Dearman RJ; Kimber I Selective down-regulation of T cell-and non-T cell-derived tumour necrosis factor alpha by thalidomide: comparisons with dexamethasone | 10 | 13 |
| 1482 | 13 | 23 | 1213 2001 INTERNATIONAL IMMUNOPHARMACOLOGY 1(1):49-61 Rowland TL; McHugh SM; Deighton J; Ewan PW; Dearman RJ; Kimber I Differential effect of thalidomide and dexamethasone on the transcription factor NF-kappa B | 5 | 8 |
| 1483 | 0 | 0 | 698 1998 FASEB JOURNAL 12(4):A262-A262 Rowland TL; McHugh SM; Ewan PW; Lachmann PJ; Dearman RJ; Kimber I Down-regulation of T-cell and non-T-cell derived tumor necrosis factor alpha by thalidomide and dexamethasone | 0 | 0 |
| 1484 | 3 | 10 | 842 1999 LUPUS 8(3):248-249 Rua-Figueroa I; Erausquin C; Naranjo A; Carretero-Hernandez G; Rodriguez-Lozano C; De la Rosa P Pustuloderma during cutaneous lupus treatment with thalidomide | 3 | 5 |
| 1485 | 0 | 0 | 102 1983 ZEITSCHRIFT FUR ORTHOPADIE UND IHRE GRENZGEBIETE 121(4):526-526 RUFFING L DISTURBANCES OF DISK DIFFERENTIATION DUE TO THALIDOMIDE | 0 | 0 |
| 1486 | 3 | 13 | 284 1990 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 23(5):941-944 RUSTIN MHA; GILKES JJH; ROBINSON TWE PYODERMA-GANGRENOSUM ASSOCIATED WITH BEHCETS-DISEASE - TREATMENT WITH THALIDOMIDE | 14 | 27 |
| 1487 | 0 | 0 | 584 1997 BRITISH MEDICAL JOURNAL 315(7110):699-699 Rutter T Thalidomide ban to be lifted in the US | 1 | 1 |
| 1488 | 2 | 2 | 984 2000 GUT 47(1):156-156 Ryan J Thalidomide treatment of oesophageal ulceration | 0 | 0 |
| 1489 | 6 | 9 | 335 1992 NEW ENGLAND JOURNAL OF MEDICINE 327(3):208-209 RYAN J; COLMAN J; PEDERSEN J; BENSON E THALIDOMIDE TO TREAT ESOPHAGEAL ULCER IN AIDS | 24 | 33 |
| 1490 | 21 | 36 | 1283 2002 ALIMENTARY PHARMACOLOGY & THERAPEUTICS 16(6):1117-1124 Sabate JM; Villarejo J; Lemann M; Bonnet J; Allez M; Modigliani R An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease | 4 | 15 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1491 | 0 | 0 | 1455 2002 GASTROENTEROLOGY 122(4):A498-A498 Sabate JM; Villarejo J; Lemann M; Bonnet J; Allez M; Modigliani R An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease | 0 | 0 |
| 1492 | 0 | 0 | 766 1999 BLOOD 94(10):125A-125A Sabir T; Raza S; Anderson L; Jagannath S Thalidomide is effective in the treatment of recurrent. Refractory multiple myeloma (MM). | 0 | 7 |
| 1493 | 6 | 11 | 793 1999 CLINICAL NEUROPHYSIOLOGY 110(4):735-739 Sadoh DR; Hawk JLM; Panayiotopoulos CP F-chronodispersion in patients on thalidomide | 5 | 5 |
| 1494 | 0 | 8 | 431 1995 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 122(9):609-611 Safa G; Joly P; Boullie MC; Thomine E; Lauret P Treatment of 2 cases of Melkersson-Rosenthal syndrome with thalidomide | 3 | 8 |
| 1495 | 0 | 0 | 1660 2003 BLOOD 102(11):984A-984A Sahebi F; Somlo G; Kogut NM; Falk PM; Spielberger R; Parker PM; Krishnan A; Frankel P; Kosobayashi N; Forman SJ Feasibility and toxicity of maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma | 0 | 0 |
| 1496 | 0 | 0 | 129 1984 TERATOLOGY 30(1):A26-A27 SAITO T; ASAKA A; KANNO O; KIDA M PSYCHOLOGICAL-TESTS AND A STUDY OF SOCIAL-ADJUSTMENT OF PATIENTS WITH THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| 1497 | 0 | 6 | 233 1988 INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES 56(4):625-625 SALAFIA A; KHARKAR RD THALIDOMIDE AND EXFOLIATIVE DERMATITIS | 6 | 6 |
| 1498 | 0 | 0 | 425 1994 REVISTA BRASILEIRA DE GENETICA 17(4):449-464 SALDANHA PH THE THALIDOMIDE-TRAGEDY AND THE BIRTH OF EXPERIMENTAL TERATOLOGY | 0 | 0 |
| 1499 | 17 | 42 | 1308 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):13-19 Sampaio EP; Hernandez MO; Carvalho DS; Sarno EN Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M-leprae-induced TNF alpha production in vitro | 5 | 6 |
| 1500 | 1 | 23 | 365 1993 JOURNAL OF INFECTIOUS DISEASES 168(2):408-414 SAMPAIO EP; KAPLAN G; MIRANDA A; NERY JAC; MIGUEL CP; VIANA SM; SARNO EN THE INFLUENCE OF THALIDOMIDE ON THE CLINICAL AND IMMUNOLOGICAL MANIFESTATION OF ERYTHEMA-NODOSUM LEPROSUM | 141 | 212 |